Filtered By:
Therapy: Radiation Therapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 3191 results found since Jan 2013.
A Case of Hepatocellular Carcinoma Showing Tumor Shrinkage due to an Abscopal Effect
Intern Med. 2023 May 17. doi: 10.2169/internalmedicine.1844-23. Online ahead of print.ABSTRACTWe herein report a 63-year-old man who presented with left lower jaw pain and was diagnosed with hepatocellular carcinoma with bone metastases post-examination. All tumors grew after immunotherapy with atezolizumab and bevacizumab, and his jaw pain worsened. After palliative radiation therapy, however, the tumors shrank markedly, with no recurrence seen after stopping immunotherapy. To our knowledge, this is the first case in which a radiotherapy- and immunotherapy-mediated abscopal effect facilitated tumor shrinkage and immunothe...
Source: Internal Medicine - May 17, 2023 Category: Internal Medicine Authors: Ryo Yano Masashi Hirooka Makoto Morita Yuki Okazaki Yoshiko Nakamura Yusuke Imai Takao Watanabe Yohei Koizumi Osamu Yoshida Yoshio Tokumoto Masanori Abe Yoichi Hiasa Source Type: research
Palliative Arterial Embolization for Metastases of the Sternum
ConclusionArterial embolization is safe and effective as a palliative treatment for patients with metastases of the sternum who did not benefit from radiation therapy or experienced recurrence in symptoms.
Source: CardioVascular and Interventional Radiology - May 15, 2023 Category: Radiology Source Type: research
Case –control study analyzing the relationship between oral microcirculation and oral mucositis and pain in patients under antineoplastic therapy
AbstractThe study aimed to evaluate the relation between microcirculation of the genian region using laser Doppler flowmetry and oral mucositis (OM) and pain in individuals undergoing antineoplastic therapy. A case –control clinical study was conducted with the participants divided into three groups: chemotherapy (CTG), radiation therapy and chemotherapy group (RCTG), and control group (CG). Pain was assessed by visual analog scale; OM was classified by oral mucositis assessment and WHO scales. The blood flo w was assessed by laser Doppler flowmetry. Kruskal–Wallis statistical test, Friedman test, and Spearman test wer...
Source: Lasers in Medical Science - May 8, 2023 Category: Laser Surgery Source Type: research
Long-Term Patient-Reported Quality of Life of Anal Cancer Survivors Treated with Intensity Modulated Radiation Therapy and Concurrent Chemotherapy: Results from a Prospective Phase II trial
CONCLUSIONS: When compared with historical data, IMRT is associated with reduced long-term impacts on QOL. The majority of patients treated with IMRT experienced clinically significant recovery of function and improvement in QOL over 5 years after completion of treatment. The study noticed that specific toxicities such as chronic diarrhea, fecal incontinence urinary and sexual dysfunction were primarily responsible for deterioration of the long-term QOL. Future research aimed at reducing such toxicities is needed to further improve long-term QOL in anal cancer.PMID:37148982 | DOI:10.1016/j.ijrobp.2023.04.023
Source: Cancer Control - May 6, 2023 Category: Cancer & Oncology Authors: Kurian Joseph Mustafa Al Balushi Sunita Ghosh Trevor Stenson Aswin Abraham Arun Elangovan Heather Warkentin Kim Paulson Keith Tankel Nawaid Usmani Diane Severin Dan Schiller Clarence Wong Karen Mulder Corinne Doll Karen King Tirath Nijjar Source Type: research
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
CONCLUSION: Metronomic chemotherapy, especially capecitabine added to the targeted therapy, imatinib, is a potentially useful treatment for PDC where no other options are available, especially those harbouring no mutation in the dominant four genes. Indeed, the absence of mutation with KIT amplification could be a potential marker for improved outcomes with targeted and metronomic therapy, which deserves further evaluation in a clinical trial setting.PMID:37138969 | PMC:PMC10151079 | DOI:10.3332/ecancer.2023.1535
Source: Ecancermedicalscience - May 4, 2023 Category: Cancer & Oncology Authors: Sana Al-Sukhun Karim Khalidi Source Type: research
